Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Nervous System Active Pharmaceutical Ingredients Market size was valued at USD 219.45 billion in 2024 and is expected to reach USD 403.68 billion by 2037, registering around 4.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of nervous system active pharmaceutical ingredients is assessed at USD 236.63 billion.
The reason behind the growth is impelled by the growing presence of chronic diseases across the globe. This as a result is increasing the demand for active pharmaceutical ingredients as they are largely used to treat both acute and chronic pain.
The nervous system gets affected by several chronic disorders which necessitates the use of nervous system active pharmaceutical ingredients to help patients in managing these conditions. Every year, 17 million death take place globally owing to chronic diseases.
The growing geriatric population is believed to fuel the market growth. The elderly population is more prone to several neurological diseases such as Alzheimer’s, and Parkinson’s disease, and the rising number of elderly populations across the globe is estimated to drive market growth. Nervous system APIs help in managing the symptoms of these disorders and also help in pain management resulting from other age-related diseases. According to estimates, the number of individuals in the world who are 60 or older will rise to over 2 billion by 2050.
Nervous System Active Pharmaceutical Ingredients Sector: Growth Drivers and Challenges
Growth Drivers
- Growing Popularity of Personalized Medicines- The healthcare system is paying more attention to precision medicine since it enables more individualized treatments. Nervous system active pharmaceutical ingredients are utilized in personalized medicine approaches, which is estimated to drive market growth.
- Rising Focus on Mental Health- The pandemic also contributed to a greater focus on mental health, which has resulted in a rise in demand for mental health treatments including nervous system active pharmaceutical ingredients.
Challenges
- Availability of Counterfeit Drugs– The availability of substandard counterfeit medicines is expected to hinder market growth during the forecast period. For instance, counterfeit drugs are available everywhere around the world and customers find them cost-effective and convenient.
- Shortage of the Required Ingredients
- Lack of Awareness of Medication
Nervous System Active Pharmaceutical Ingredients Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
4.8% |
|
Base Year Market Size (2024) |
USD 219.45 billion |
|
Forecast Year Market Size (2037) |
USD 403.68 billion |
|
Regional Scope |
|
Nervous System Active Pharmaceutical Ingredients Segmentation
Application (Diabetes, CVDs, Oncology, Neurological Disorder)
The CVDs segment is estimated to gain a robust market share in the coming years owing to the growing demand for nervous system APIs for effective treatments. Several nervous system active pharmaceutical systems are used to treat cardiovascular diseases, such as beta-blockers, and ACE inhibitors. Moreover, for the management of high blood pressure, ACE inhibitors and beta-blockers are utilized, and they are considered among the first-line treatment for heart failure and are highly successful in treating numerous cardiovascular illnesses. Moreover, in terms of decreasing blood pressure, (Angiotensin-converting enzymes) ACE inhibitors and beta-blockers are both equally effective since they can relax blood vessels in addition to reducing heart rate by blocking angiotensin-2.
Our in-depth analysis of the global market includes the following segments:
|
Product |
|
|
Application |
|
|
Expression System |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportNervous System Active Pharmaceutical Ingredients Industry - Regional Synopsis
Asia Pacific industry is predicted to account for largest revenue share of 30% by 2037, impelled by the rising spending in healthcare. This, as a result, helps the pharmaceutical companies in the region to allocate more resources for the development of new nervous system active pharmaceutical ingredients to combat several neurological and cardiovascular diseases.
Besides this, rising investment in healthcare may also enable the development of novel drug delivery systems in the region for neurological diseases which necessitates the usage of nervous system APIs. According to data, the US spends the most on healthcare, and in 2021, health expenditures in the United States rose by more than 2%.
APAC Market Statistics
The Asia Pacific nervous system active pharmaceutical ingredients market is estimated to be the second largest share of 30%, during the forecast timeframe led by low labor costs. For instance, owing to the availability of cheap labor in countries such as India and Indonesia results in increasing production capacity for nervous system active pharmaceutical ingredients which can lead to an increased demand for these APIs in both local and international markets.
Companies Dominating the Nervous System Active Pharmaceutical Ingredients Landscape
- Pfizer, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb Company
- Shenzhen Hepalink Pharmaceutical Co. Ltd.
- GSK plc
- F. Hoffmann-La Roche Ltd
- Cipla Inc.
- Eli Lilly and Company
- Novartis AG,
- Teva Pharmaceutical Industries Ltd.
In the News
- Boehringer Ingelheim International GmbH to partner with Carthronix, a biopharmaceutical company to develop therapies based on small molecules to cure diseases associated with elderly people. The research & development are further associated with small molecule therapeutics in canine oncology.
- F. Hoffmann-La Roche Ltd to acquire acceptance from FDA for its Biologics License Applications. The application is associated with untreated diffuse large B-cell lymphoma.
Author Credits: Rajrani Baghel
- Report ID: 4212
- Published Date: Dec 20, 2024
- Report Format: PDF, PPT
